Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases

PLoS Computational Biology

Volumn 7, Issue 10, 2011, Pages

  Dixit, Anshuman ^a   Verkhivker, Gennady M ^a,b,c  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHAPMAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; CLASSIFICATION (OF INFORMATION); COMPLEX NETWORKS; COMPUTATION THEORY; DISEASES; ENZYMES;

ALLOSTERIC ACTIVATION; ALLOSTERIC COMMUNICATION; ALLOSTERIC INHIBITOR; COMPUTATIONAL MODELLING; KINASE COMPLEX; LONG-RANGE COMMUNICATIONS; MECHANISTIC ASPECTS; PROTEIN KINASE; REGULATORY COMPLEXES; STRUCTURAL INFORMATION;

BINDING SITES;

ABELSON KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ALLOSTERISM; ALPHA HELIX; ARTICLE; BINDING SITE; COMPLEX FORMATION; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME STRUCTURE; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; ENZYME ACTIVE SITE; GENETICS; HUMAN; METABOLISM; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE;

ALLOSTERIC REGULATION; CATALYTIC DOMAIN; COMPUTATIONAL BIOLOGY; DIMERIZATION; ENZYME ACTIVATION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 80053590126     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002179     Document Type: Article

References (182)

1. Koshland DE, Némethy G, Filmer D, (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5: 365-385.
2. Monod J, Wyman J, Changeux JP, (1965) On the nature of allosteric transitions: A plausible model. J Mol Biol 12: 88-118.
3. Cui Q, Karplus M, (2008) Allostery and cooperativity revisited. Protein Sci 17: 1295-1307.
4. Goodey NM, Benkovic SJ, (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4: 474-482.
5. Tsai CJ, Sol AD, Nussinov R, (2008) Allostery: absence of a change in shape does not imply that allostery is not at play. J Mol Biol 378: 1-11.
6. Tsai CJ, Sol AD, Nussinov R, (2009) Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol Biosyst 5: 207-216.
7. Sol AD, Sol, Tsai CJ, Ma B, Nussinov R, (2009) The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 17: 1042-1050.
8. Lockless SW, Ranganathan R, (1999) Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286: 295-299.
9. Suel GM, Lockless SW, Wall MA, Ranganathan R, (2003) Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat Struct Biol 10: 59-69.
10. Del-Sol AH, Fujihashi H, Amoros D, Nussinov R, (2006) Residues crucial for maintaining short paths in network communication mediate signaling in proteins. Mol Syst Biol 0019.
11. Del Sol AH, Arauzo Bravo MJ, Amoros D, Nussinov R, (2007) Modular architecture of protein structures and allosteric communications: potential implications for signaling proteins and regulatory linkages. Genome Biol 8: R92.
12. Zandany NM, Ovadia M, OrrI I, Yifrach O, (2008) Direct analysis of cooperativity in multisubunit allosteric proteins. Proc Natl Acad Sci U S A 105: 11697-702.
13. Xu C, Tobi D, Bahar I, (2003) Allosteric changes in protein structure computed by a simple mechanical model: hemoglobin T-R2 transition. J Mol Biol 333: 153-168.
14. Zheng W, Brooks B, (2005) Identification of dynamical correlations within the myosin motor domain by the normal mode analysis of an elastic network model. J Mol Biol 346: 745-759.
15. Dima RI, Thirumalai D, (2006) Determination of network of residues that regulate allostery in protein families using sequence analysis. Protein Sci 15: 258-268.
16. Zheng W, Brooks BR, Thirumalai D, (2006) Low-frequency normal modes that describe allosteric transitions in biological nanomachines are robust to sequence variations. Proc Natl Acad Sci U S A 103: 7664-7669.
17. Hyeon C, Lorimer GH, Thirumalai D, (2006) Dynamics of allosteric transitions in GroEL. Proc Natl Acad Sci U S A 103: 18939-18944.
18. Stan G, Lorimer GH, Thirumalai D, Brooks BR, (2007) Coupling between allosteric transitions in GroEL and assisted folding of a substrate protein. Proc Natl Acad Sci U S A 104: 8803-8808.
19. Zheng W, Brooks BR, Thirumalai D, (2007) Allosteric transitions in the chaperonin GroEL are captured by a dominant normal mode that is most robust to sequence variations. Biophys J 93: 2289-2299.
20. Chen J, Dima RI, Thirumalai D, (2007) Allosteric communication in dihydrofolate reductase: signaling network and pathways for closed to occluded transition and back. J Mol Biol 374: 250-266.
21. Tehver R, Chen J, Thirumalai D, (2009) Allostery wiring diagrams in the transitions that drive the GroEL reaction cycle. J Mol Biol 387: 390-406.
22. Zheng W, Thirumalai D, (2009) Coupling between normal modes drives protein conformational dynamics: illustrations using allosteric transitions in myosin II. Biophys J 96: 2128-2137.
23. Zheng W, Tekpinar M, (2009) Large-scale evaluation of dynamically important residues in proteins predicted by the perturbation analysis of a coarse-grained elastic model. BMC Struct Biol 9: 45.
24. Zheng W, Brooks BR, Thirumalai D, (2009) Allosteric transitions in biological nanomachines are described by robust normal modes of elastic networks. Curr Protein Pept Sci 10: 128-132.
25. Yang L, Song G, Jernigan RL, (2009) Protein elastic network models and the ranges of cooperativity. Proc Natl Acad Sci U S A 106: 12347-12352.
26. Chennubhotla C, Bahar I, (2006) Markov propagation of allosteric effects in biomolecular systems: application to GroEL-GroES. Mol Syst Biol 2: 36.
27. Chennubhotla C, Bahar I, (2007) Signal propagation in proteins and relation to equilibrium fluctuations. PLoS Comput Biol 3: 1716-1726.
28. Bahar I, Chennubhotla C, Tobi D, (2007) Intrinsic dynamics of enzymes in the unbound state and relation to allosteric regulation. Curr Opin Struct Biol 17: 633-640.
29. Chennubhotla C, Yang Z, Bahar I, (2008) Coupling between global dynamics and signal transduction pathways: a mechanism of allostery for chaperonin GroEL. Mol Biosyst 4: 287-292.
30. Isin, B, Schulten K, Tajkhorshid E, Bahar I, (2008) Mechanism of signal propagation upon retinal isomerization: insights from molecular dynamics simulations of rhodopsin restrained by normal modes. Biophys J 95: 789-803.
31. Yang Z, Majek P, Bahar I, (2009) Allosteric transitions of supramolecular systems explored by network models: application to chaperonin GroEL. PLoS Comput Biol 5: e1000360.
32. Kidd BA, Baker D, Thomas WE, (2009) Computation of conformational coupling in allosteric proteins. PLoS Comput Biol 5: e1000484.
33. Daily MD, Gray JJ, (2007) Local motions in a benchmark of allosteric proteins. Proteins 67: 385-399.
34. Daily MD, Upadhyaya TJ, Gray JJ, (2008) Contact rearrangements form coupled networks from local motions in allosteric proteins. Proteins 71: 455-466.
35. Daily MD, Gray JJ, (2009) Allosteric communication occurs via networks of tertiary and quaternary motions in proteins. PLoS Comput Biol 5: e1000293.
36. Demerdash ONA, Daily MD, Mitchell JC, (2009) Structure-based predictive models for allosteric hot spots. PLoS Comput Biol 5: e1000531.
37. Ma J, Karplus M, (1998) The allosteric mechanism of the chaperonin GroEL: a dynamic analysis. Proc Natl Acad Sci U S A 95: 8502-8507.
38. Ma J, Sigler PB, Xu Z, Karplus M, (2000) A dynamic model for the allosteric mechanism of GroEL. J Mol Biol 302: 303-313.
39. Formaneck MS, Ma L, Cui Q, (2006) Reconciling the "old" and "new" views of protein allostery: a molecular simulation study of chemotaxis Y protein (CheY). Proteins 63: 846-867.
40. Kong Y, Ma J, Karplus M, Lipscomb WN, (2006) The allosteric mechanism of yeast chorismate mutase: A dynamic analysis. J Mol Biol 356: 237-247.
41. Yu H, Ma L, Yang Y, Cui Q, (2007) Mechanochemical coupling in the myosin motor domain. I. insights from equilibrium active-site simulations. PLoS Comput Biol 3: e21.
42. Yu H, Ma L, Yang Y, Cui Q, (2007) Mechanochemical coupling in the myosin motor domain. ii. analysis of critical residues. PLoS Comput Biol 3: e23.
43. Ma L, Cui Q, (2007) Activation mechanism of a signaling protein at atomic resolution from advanced computations. J Am Chem Soc 129: 10261-10268.
44. Yang Y, Yu H, Cui Q, (2008) Extensive conformational transitions are required to turn on atp hydrolysis in myosin. J Mol Biol 381: 1407-1420.
45. Cecchini M, Houdusse A, Karplus M, (2008) Allosteric communication in myosin V: From small conformational changes to large directed movements. PLoS Comput Biol 4: e1000129.
46. Pan H, Lee JC, Hilser VJ, (2000) Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci U S A 97: 12020-12025.
47. Liu T, Whitten ST, Hilser VJ, (2007) Functional residues serve a dominant role in mediating the cooperativity of the protein ensemble. Proc Natl Acad Sci USA 104: 4347-4352.
48. Sayar K, Uǧur O, Liu T, Hilser VJ, Onaran O, (2008) Exploring allosteric coupling in the alpha-subunit of heterotrimeric G proteins using evolutionary and ensemble-based approaches. BMC Struc Biol 8: 23.
49. Onaran HO, Costa T, (2009) Allosteric coupling and conformational fluctuations in proteins. Curr Protein Pept Sci 10: 110-115.
50. Ota N, Agard DA, (2005) Intramolecular signaling pathways revealed by modeling anisotropic thermal diffusion. J Mol Biol 351: 345-354.
51. Ho BK, Agard DA, (2009) Probing the flexibility of large conformational changes in protein structures through local perturbations. PLoS Comput Biol 5: e1000343.
52. Vendruscolo MN, Dokholyan V, Paci E, Karplus M, (2002) Small-world view of the amino acids that play a key role in protein folding. Phys Rev E Stat Nonlin Soft Matter Phys 65: 061910.
53. Atilgan A R, Akan P, Baysal C, (2004) Small-world communication of residues and significance for protein dynamics. Biophys J 86: 85-91.
54. del Sol A, O'Meara P, (2005) Small-world network approach to identify key residues in protein-protein interaction. Proteins 58: 672-682.
55. del Sol A, Fujihashi H, O'Meara P, (2005) Topology of small-world networks of protein-protein complex structures. Bioinformatics 21: 1311-1315.
56. del Sol A, Fujihashi H, Amoros D, Nussinov R, (2006) Residue centrality, functionally important residues, and active site shape: analysis of enzyme and non-enzyme families. Protein Sci 15: 2120-2128.
57. Chea E, Livesay DR, (2007) How accurate and statistically robust are catalytic site predictions based on closeness centrality? BMC Bioinformatics 8: 153.
58. Barrat A, Barthelemy M, Vespignani A, (2004) Modeling the evolution of weighted networks. Phys Rev E Stat Nonlin Soft Matter Phys 70: 066149.
59. Barrat A, Barthelemy M, Pastor-Satorras R, Vespignani A, (2004) The architecture of complex weighted networks. Proc Natl Acad Sci USA 101: 3747-3752.
60. Jiao X, Chang S, Li CH, Chen WZ, Wang CX, (2007) Construction and application of the weighted amino acid network based on energy. Phys Rev E Stat Nonlin Soft Matter Phys 75: 051903.
61. Serrano MA, Boguna M, Vespignani A, (2009) Extracting the multiscale backbone of complex weighted networks. Proc Natl Acad Sci USA 106: 6483-6488.
62. Shi Z, Resing KA, Ahn NG, (2006) Networks for the allosteric control of protein kinases. Curr Opin Struct Biol 16: 686-692.
63. Pellicena P, Kuriyan J, (2006) Protein-protein interactions in the allosteric regulation of protein kinases. Curr Opin Struct Biol 16: 702-709.
64. Kannan N, Neuwald AF, (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351: 956-972.
65. Kannan N, Haste N, Taylor SS, Neuwald AF, (2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci U S A 104: 1272-1277.
66. Kornev AP, Haste NM, Taylor SS, Eyck LF, (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A 103: 17783-17788.
67. Kornev AP, Taylor SS, Ten Eyck LF, (2008) A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A 105: 14377-14382.
68. Kornev AP, Taylor SS, (2010) Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 1804: 440-444.
69. Taylor SS, Kornev AP, (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36: 65-77.
70. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, et al. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942.
71. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236-4243.
72. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants. Cancer Res 66: 5790-5797.
73. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, et al. (2006) Structure of the kinase domain of an Imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 6: 1007-1014.
74. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67: 7987-7990.
75. Zhou T, Parillon L, Li F, Wang Y, Keats J, et al. (2007) Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 70: 171-181.
76. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ, (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-1118.
77. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
78. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
79. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075.
80. Lee GM, Craik CS, (2009) Trapping moving targets with small molecules. Science 324: 213-215.
81. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, et al. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283: 18292-18302.
82. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ, (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17: 212-221.
83. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
84. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW, (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611-4614.
85. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
86. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505.
87. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Ray A, et al. (2005) Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl. Cancer Cell 7: 129-141.
88. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL, (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102: 3395-3400.
89. Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, et al. (2006) Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 103: 9244-9249.
90. Bantscheff MD, Eberhard Y, Abraham S, Bastuck M, Boesche S, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044.
91. Rix UO, Hantschel G, Dürnberger LL, Remsing R, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063.
92. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412.
93. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, et al. (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77: 1-11.
94. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115: 4206-4216.
95. Knight ZA, Shokat KM, (2005) Features of selective kinase inhibitors. Chem Biol 12: 621-637.
96. Liu Y, Gray NS, (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2: 358-364.
97. Okram B, Nagle A, Adrian FJ, Lee C, Ren P, et al. (2006) A general strategy for creating ïnactive-conformation" abl inhibitors. Chem Biol 13: 779-786.
98. Fabian MA, William, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.
99. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
100. Zhang J, Yang PL, Gray NS, (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
101. Simard JR, Kluter S, Grutter C, Getlik M, Rabiller M, et al. (2009) A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol 5: 394-396.
102. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, et al. (2004) Structures of human MAP kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197.
103. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, et al. (2009) Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48: 2661-2674.
104. Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, et al. (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci USA 105: 16809-16813.
105. Heo Y.-S, Kim S-K, Seo CI, Kim YK, Sung B-J, et al. (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 23: 2185-2195.
106. Chen T, Kablaoui N, Little J, Timofeevski S, Tschantz WR, et al. (2009) Identification of small-molecule inhibitors of the JIP-JNK interaction. Biochem J 420: 283-294.
107. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach DR, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-871.
108. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, et al. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 21: 787-798.
109. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, et al. (2006) A SRC-like inactive conformation in the ABL tyrosine kinase domain. PLoS Biol 4: 0753-0767.
110. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, et al. (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15: 299-311.
111. Iacob RE, Pene-Dumitrescu T, Zhang J, Gray NS, Smithgall TE, et al. (2009) Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci U S A 106: 1386-1391.
112. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2: 95-102.
113. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
114. Iacob RE, Zhang J, Gray NS, Engen JR, (2011) Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 6: e15929.
115. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, et al. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376: 313-320.
116. Russo AA, Jeffrey PD, Pavletich NP, (1996) Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 8: 696-700.
117. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J, (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
118. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741-744.
119. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, et al. (2008) 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci U S A 1058: 2773-2778.
120. Jura N, Endres NF, Engel K, Deindl S, Das R, et al. (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137: 1293-1307.
121. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, et al. (2009) The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34: 641-651.
122. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J, (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U SA 106: 21608-21613.
123. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, et al. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2. J Biol Chem 286: 18756-65.
124. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, et al. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16: 460-467.
125. Monsey J, Shen W, Schlesinger P, Bose R, (2010) Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 285: 7035-7044.
126. Yang J, Cron P, Thompson V, Good VM, Hess D, et al. (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9: 1227-1240.
127. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, et al. (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9: 940-944.
128. Calleja V, Laguerre M, Parker PJ, Larijani B, (2009) Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 7: e17.
129. Calleja V, Laguerre M, Larijani B, (2009) 3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol 2: 11-25.
130. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408.
131. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, et al. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15: 761-764.
132. Engel M, Hindie V, Lopez-Garcia LA, Stroba A, Schaeffer F, et al. (2006) Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J 25: 5469-5480.
133. Stockman BJ, Kothe M, Kohls D, Weibley L, Connolly BJ, et al. (2009) Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem Biol Drug Des 73: 179-188.
134. Dawson JP, Bu Z, Lemmon MA, (2007) Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 15: 942-954.
135. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-11134.
136. Bae JH, Schlessinger J, (2010) Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol Cells 29: 443-448.
137. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, et al. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42: 9-22.
138. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J, (2001) Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 105: 115-126.
139. Mendieta J, Gago F, (2004) In silico activation of Src tyrosine kinase reveals the molecular basis for intramolecular autophosphorylation. J Mol Graphics Model 23: 189-198.
140. Ozkirimli E, Post CB, (2006) Src kinase activation: A switched electrostatic network. Protein Sci 15: 1051-1062.
141. Ozkirimli E, Yadav SS, Miller WT, Post CB, (2008) An electrostatic network and long-range regulation of Src kinases. Protein Sci 17: 1871-1880.
142. Banavali NK, Roux B, (2007) Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck. Proteins 67: 1096-1112.
143. Yang S, Roux B, (2008) Src kinase conformational activation: Thermodynamics, pathways, and mechanisms. PLoS Comput Biol 4: e1000047.
144. Banavali NK, Roux B, (2009) Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Proteins 74: 378-389.
145. Yang S, Banavali NK, Roux B, (2009) Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A 106: 3776-3781.
146. Arora K, Brooks CL 3rd, (2007) Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism. Proc Natl Acad Sci U S A 104: 18496-18501.
147. Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MØ, et al. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A 106: 139-144.
148. Berteotti A, Cavalli A, Branduardi D, Gervasio FL, Recanatini M, et al. (2009) Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. J Am Chem Soc 131: 244-250.
149. Zou J, Wang YD, Ma FX, Xiang ML, Shi B, et al. (2008) Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 72: 323-332.
150. Hyeon C, Jennings PA, Adams, Onuchic JN, (2009) Ligand-induced global transitions in the catalytic domain of protein kinase A. Proc Natl Acad Sci U S A 106: 3023-3028.
151. Cheng S, Niv MY, (2010) Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt/PKB) inactivation. J Chem Inf Model 50: 1602-1610.
152. Dixit A, Torkamani A, Schork NJ, Verkhivker G, (2009) Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96: 858-874.
153. Torkamani A, Verkhivker G, Schork NJ, (2009) Cancer Lett 281: 117-127.
154. Papakyriakou A, Vourloumis D, Tzortzatou-Stathopoulou F, Karpusas M, (2008) Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins 76: 375-386.
155. Dixit A, Verkhivker G, (2009) Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol 5: e1000487.
156. Mirza A, Mustafa M, Talevich E, Kannan N, (2010) Co-conserved features associated with cis regulation of ErbB tyrosine kinases. PLoS One 5: e14310.
157. Mustafa M, Mirza A, Kannan N, (2011) Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study. Proteins 79: 99-114.
158. Telesco SE, Radhakrishnan R, (2009) Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. Biophys J 96: 2321-2334.
159. Telesco SE, Shih AJ, Jia F, Radhakrishnan R, (2011) A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol Biosyst 7: 2066-2080.
160. Shih AJ, Telesco SE, Choi SH, Lemmon MA, Radhakrishnan R, (2011) Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Biochem J 436: 241-251.
161. Meli M, Verkhivker GM, Colombo G, (2009) Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full length dimer. PLoS Comput Biol 5: e1000323.
162. Verkhivker GM, Dixit A, Morra G, Colombo G, (2009) Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design. Curr Top Med Chem 9: 1369-1385.
163. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
164. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316.
165. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377.
166. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711.
167. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932.
168. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, et al. (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81-93.
169. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, et al. (2008) The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 7: 874-879.
170. Kumar A, Petri ET, Halmos B, Boggon TJ, (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751.
171. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, et al. (2007) Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 13: 3713-3723.
172. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
173. Marti-Renom MA, Stuart A, Fiser A, Sánchez R, Melo A, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325.
174. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
175. MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL Jr, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586-3616.
176. MacKerell AD Jr, Banavali N, Foloppe N, (2001) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56: 257-265.
177. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, et al. (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
178. Eargle J, Wright D, Luthey-Schulten Z, (2006) Multiple alignment of protein structures and sequences for VMD. Bioinformatics 22: 504-506.
179. Amadei A, Linssen AB, Berendsen HJ, (1993) Essential dynamics of proteins. Proteins 17: 412-425.
180. Amadei A, Ceruso MA, Di Nola A, (1999) On the convergence of the conformational coordinates basis set obtained by the essential dynamics analysis of proteins' molecular dynamics simulations. Proteins 36: 419-424.
181. Glykos NM, (2006) Software news and updates. Carma: a molecular dynamics analysis program. J Comput Chem 27: 1765-1768.
182. Yang LW, Eyal E, Bahar I, Kitao A, (2009) Principal component analysis of native ensembles of biomolecular structures (PCA_NEST): insights into functional dynamics. Bioinformatics 25: 606-614.